Study uncovers key differences among ALS patients
Researchers on Mayo Clinic's Florida campus have identified key differences between patients with sporadic amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and those with the most common genetic form of ALS, a mutation in the C9orf72 gene.
Their findings, reported online in Nature Neuroscience, demonstrate that ALS patients show abnormalities in levels and processing of ribonucleic acids (RNA).
More than 30,000 Americans live with ALS, a condition that destroys motor neuron cells that control essential muscle activity, such as speaking, walking, breathing and swallowing. While increasing efforts are geared toward therapeutic development, an effective drug for ALS has yet to be identified, in large part because of our incomplete understanding of the disease.
"Our results using advanced, modern laboratory techniques called next-generation sequencing, allowed us to acquire a library of new knowledge about patients with ALS," says the study's senior author, Leonard Petrucelli, Ph.D., chair of the Department of Neuroscience on Mayo Clinic's Florida campus.
Dr. Petrucelli and Hu Li, Ph.D., assistant professor of pharmacology on Mayo Clinic's campus in Rochester, Minn., led a team of investigators who carefully analyzed the RNA from human brain tissues. They found that ALS brains had numerous RNA defects, compared to nondisease brains. They also predicted molecular events that may be altered due to the changes found in RNAs involved in pathways regulating those events and that may contribute to ALS.
While the researchers observed some commonalities, they also found many distinctions between the RNAs that were altered in sporadic versus C9orf72 mutation-associated cases. This suggests there may be different factors contributing to ALS in patients. The success of future therapies may need specific tailoring to the specific root cause of a patient's motor neuron disease. Furthermore, the large volume of data obtained from their study, which was deposited into a public genomics data repository, provides a wealth of information available to other researchers to accelerate ALS research.
Key to the success of their study was procuring samples from individuals who generously donated their tissues for research purposes to the Mayo Clinic after their passing. Close collaborations among the Petrucelli laboratory, Kevin Boylan, M.D., director of the ALS Certified Center of Excellence on Mayo's Florida campus, and Dennis Dickson, M.D., director of the neuropathology laboratory on the Florida campus, facilitated access to these precious samples.
"Last year, the ALS Ice Bucket Challenge raised a remarkable amount of money to support ALS patients and research," Dr. Petrucelli says. "Without the extreme generosity of both monetary donors and patient tissue donors we could not make these strides in understanding this devastating disease."
The Petrucelli laboratory is conducting follow-up studies based on the data from this study to determine which alterations are important in ALS pathogenesis. The researchers also will study which alterations should be developed as diagnostic and prognostic biomarkers or as therapeutic targets that may offer hope to patients with ALS.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Petrucelli L et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nature Neuroscience, Published Online July 20 2015. doi: 10.1038/nn.4065